AC Immune SA Holds Annual Meeting, Updates Shareholders

Ticker: ACIU · Form: 6-K · Filed: Jun 20, 2024 · CIK: 1651625

Ac Immune SA 6-K Filing Summary
FieldDetail
CompanyAc Immune SA (ACIU)
Form Type6-K
Filed DateJun 20, 2024
Risk Levellow
Pages4
Reading Time4 min
Sentimentneutral

Sentiment: neutral

Topics: agm, corporate-governance, shareholder-meeting

TL;DR

AC Immune held its AGM on June 20, 2024, with an operational update and voting results; some agenda items were withdrawn.

AI Summary

On June 20, 2024, AC Immune SA held its Annual General Meeting of Shareholders. The company provided an operational update and announced the final voting results on agenda items. The board of directors withdrew agenda items 6.1, 6.2, and 6.3 prior to the meeting. The amended Articles of Association will be published on the company's investor relations website.

Why It Matters

This filing provides transparency on shareholder voting outcomes and operational progress, which can influence investor confidence and strategic direction.

Risk Assessment

Risk Level: low — The filing is a routine update on an annual general meeting and does not contain significant new financial or strategic information that would immediately alter risk.

Key Players & Entities

FAQ

What was the primary purpose of the June 20, 2024 filing?

The filing reported the final voting results of AC Immune SA's Annual General Meeting of Shareholders held on June 20, 2024, and included an operational update.

Which agenda items were withdrawn by the board of directors?

The board of directors of AC Immune SA withdrew agenda items 6.1, 6.2, and 6.3 prior to the Annual General Meeting.

Where will the amended Articles of Association be published?

The amended Articles of Association will be published on AC Immune SA's investor relations website (https://ir.acimmune.com/governance) after the filing.

What type of report is this 6-K filing?

This is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.

What is AC Immune SA's principal executive office address?

AC Immune SA's principal executive office is located at EPFL Innovation Park Building B, 1015 Lausanne, Switzerland.

Filing Stats: 1,089 words · 4 min read · ~4 pages · Grade level 16.4 · Accepted 2024-06-20 16:35:52

Filing Documents

Financial Statements and the 2023 Statutory Financial Statements

Financial Statements and the 2023 Statutory Financial Statements. Agenda Item 1.2: Advisory Vote on the 2023 Compensation Report AC Immune shareholders endorsed the 2023 Compensation Report. Agenda Item 2: Appropriation of Losses AC Immune shareholders approved that the net loss for the year 2023 in the amount of CHF 48,883K increases the “accumulated losses brought forward” of CHF 262,115K, resulting in a new balance of “accumulated losses brought forward” of CHF 310,998K. Agenda Item 3: Discharge of the Board of Directors and of the Executive Committee AC Immune shareholders approved the discharge of the members of the Board of Directors and of the Executive Committee for the financial year 2023. Agenda Item 4: Compensation for the Members of the Board of Directors and the Executive Committee Agenda Item 4.1: Binding vote on Maximum Aggregate Compensation for Members of the Board of Directors from the AGM 2024 to the AGM 2025 AC Immune shareholders approved the total maximum amount of compensation for the Board of Directors of CHF 883K (excluding employer social security contributions) covering the period from the AGM 2024 to the AGM 2025. Agenda Item 4.2: Binding vote on Maximum Aggregate Compensation for Members of the Executive Committee for the financial year 2025 AC Immune shareholders approved the total maximum compensation for the members of the Executive Committee of CHF 7,605K (excluding employer social security contributions) from 1 January 2025 to 31 December 2025. Agenda Item 5: Re-elections Agenda Item 5.1: Re-elections of Members of the Board of Directors AC Immune shareholders approved the re-election of Douglas Williams as member and as Chair of the Board of Directors and the re-election of Monika Bütler, Carl June, Werner Lanthaler, Andrea Pfeifer, Monica Shaw and Roy Twyman as members of the Board of Directors, each until the end of the Annual General Meeting 2025. Agenda Item 5.2: Re-elections

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing